Apeiba tibourbou seed oil has analgesic and anti-inflammatory effects, making it potentially useful for food and medicine.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
March 2024 in “International Journal of Dermatology” Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
April 2026 in “Phytotherapy Research” Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
March 2026 in “Stem Cell Reviews and Reports” February 2026 in “Macromolecular Bioscience” Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
2 citations
,
September 2022 in “Advances in Environmental Biology” Avicennia marina leaf extract can fight Vancomycin-resistant bacteria.
September 2022 in “Dermatologic Therapy” June 2022 in “Zenodo (CERN European Organization for Nuclear Research)” The hydrogel with neem and tridax extracts effectively treats seborrheic dermatitis.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
June 2024 in “Journal of Clinical Oncology” EGFR-TKIs can cause unexpected skin, nail, and hair issues.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
1 citations
,
March 2004 in “Military Medicine” The retired colonel's ankle swelling was caused by a reaction to the antibiotic levofloxacin.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
4 citations
,
August 2021 in “Annals of Translational Medicine” Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.